Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIS-DPI in Stage IV NSCLC
NCT06896890Phase 2Recruiting
- Sponsor
- InhaTarget Therapeutics
- Start
- Jun 2023
- Primary completion
- Oct 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 3
01
Overview
A Phase 2 trial of CIS-DPI in non-small cell lung cancer (NSCLC), sponsored by InhaTarget Therapeutics. Started Jun 2023; status: recruiting.
02
Drugs
CIS-DPI
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06896890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896890.